Randomized double blind multi-centre study of the effects on low-dose pegvisomant treatment in acromegalic subjects in whom the IGF-I levels has been normalized by long-acting somatostatin analogs.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
eggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. The Journal of clinical endocrinology and metabolism 93 (10):3853-3859.
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. The Journal of clinical endocrinology and metabolism 90 (5):2731-2739.
Bonapart IE, van Domburg R, ten Have SM, de Herder WW, Erdman RA, Janssen JA, van der Lely AJ (2005) The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. European journal of endocrinology / European Federation of Endocrine Societies 152 (2):217-224.
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Provision of written informed consent prior to any study related procedures;
- •2. Male or female aged between 18 and 75 years inclusive;
排除标准
- •1. Has undergone pituitary surgery or radiotherapy within 6 months prior to study entry;
- •2. It is anticipated that the patient will receive pituitary surgery or radiotherapy during the study;